[go: up one dir, main page]

MEP36008A - Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva - Google Patents

Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva

Info

Publication number
MEP36008A
MEP36008A MEP-360/08A MEP36008A MEP36008A ME P36008 A MEP36008 A ME P36008A ME P36008 A MEP36008 A ME P36008A ME P36008 A MEP36008 A ME P36008A
Authority
ME
Montenegro
Prior art keywords
drospirenone
ethinyl estradiol
administration
active agent
composition
Prior art date
Application number
MEP-360/08A
Other languages
English (en)
Croatian (hr)
Inventor
Wolfgang Heil
Juergen Hilman
Ralph Lipp
Renate Heithecker
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP36008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP36008A publication Critical patent/MEP36008A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Farmaceutska kompozicija koja sadrži, kao prvo aktivno sredstvo, 6ß,7ß; 15ß, 16ß-dimetilen-3-okso-17α-pregn-4-en-21, 17-karbolakton (drospirenon) u količini koja odgovara jednoj dnevnoj dozi, nakon davanja kompozicije, od oko 2mg do oko 4 mg, i kao drugo aktivno sredstvo, 17α-etinilestradiol (etinilestra-diol) u količini koja odgovara dnevnoj dozi od oko 0,01 mg do oko 0,05 mg, zajedno sa jednim ili više farmaceutski prihvatljivih nosača ili neitralnih dodataka. Kod jednog posebnog izviđenja, kompozicija se sastoji od više odvojeno pakovanih i pojedinačno odvojivih dnevnih doznih jedinica postavljenih u jednu jedinicu pakovanja I namijenjenih za oralno davanje u trajanju od najmanje 21 dan zaredom, pri čemu pomenute dnevne dozne jedinice sadrže svaka jednu kombinaciju drospirenona i etinilestradiola. Kompozicija može dalje sadržati 7 ili manje dnevnih doznih jedinica koje ne sadrže nikakvo aktivno sredstvo ili sadrže sam etinilestradiol.
MEP-360/08A 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva MEP36008A (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38627499A 1999-08-31 1999-08-31
EP99202826 1999-08-31
PCT/IB2000/001213 WO2001015701A1 (en) 1999-08-31 2000-08-31 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive

Publications (1)

Publication Number Publication Date
MEP36008A true MEP36008A (hr) 2011-02-10

Family

ID=26153359

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-360/08A MEP36008A (hr) 1999-08-31 2000-08-31 Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva
MEP-2008-360A ME00329B (me) 1999-08-31 2000-08-31 Farmaceutska kombinacija etiilestradiola i drospirenona za primjenu kao kontraceptiynog sredstva

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-360A ME00329B (me) 1999-08-31 2000-08-31 Farmaceutska kombinacija etiilestradiola i drospirenona za primjenu kao kontraceptiynog sredstva

Country Status (26)

Country Link
EP (4) EP1380301B1 (bs)
JP (2) JP4354667B2 (bs)
KR (2) KR101019361B1 (bs)
AT (3) ATE254464T1 (bs)
AU (4) AU780330B2 (bs)
BG (1) BG66114B1 (bs)
BR (1) BR0014159A (bs)
CY (3) CY1108990T1 (bs)
CZ (1) CZ300514B6 (bs)
DE (5) DE122009000006I2 (bs)
DK (3) DK1598069T3 (bs)
EE (1) EE05128B1 (bs)
ES (3) ES2211580T3 (bs)
HK (1) HK1047247B (bs)
HR (1) HRP20070188B1 (bs)
HU (1) HU227207B1 (bs)
IL (1) IL148339A0 (bs)
ME (2) MEP36008A (bs)
NO (1) NO326860B1 (bs)
NZ (1) NZ517845A (bs)
PL (1) PL199028B1 (bs)
PT (3) PT1598069E (bs)
RS (3) RS50262B (bs)
SI (3) SI1214076T1 (bs)
TW (1) TWI276436B (bs)
WO (1) WO2001015701A1 (bs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101019361B1 (ko) * 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
RS52149B (sr) * 2000-01-18 2012-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
EP1353699B1 (en) * 2000-12-20 2012-02-01 Bayer Pharma Aktiengesellschaft Beta-cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
PL372055A1 (en) * 2002-04-26 2005-07-11 Schering Aktiengesellschaft Treatment of hypertension in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP1748756B1 (en) * 2004-03-10 2009-04-29 Bayer Schering Pharma Aktiengesellschaft Compositions comprising drospirenone molecularly dispersed
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1625849A1 (en) * 2004-08-09 2006-02-15 Liconsa, Liberacion Controlada de Sustancias Activas, S.A. Pharmaceutical composition comprising drospirenone and ethynylestradiol
US8216611B2 (en) * 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1767194A1 (de) * 2005-06-09 2007-03-28 Helm AG Verfahren zur Herstellung von Adsorbaten des Drospirenons
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
EP1900359A1 (en) * 2006-09-16 2008-03-19 KAIROSmed GmbH Oral modified release formulations containing drospirenon and 8-prenylnaringenin for use in female contraception
WO2008031631A2 (en) * 2006-09-16 2008-03-20 Bayer Schering Pharma Aktiengesellschaft Oral modified release formulations
AU2008235006A1 (en) * 2007-04-05 2008-10-16 Bayer Schering Pharma Aktiengesellschaft New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
HUP0700826A3 (en) * 2007-12-20 2010-03-29 Richter Gedeon Nyrt Coated tablet containing drospirenone and process for producing the same
WO2009112232A2 (en) * 2008-03-10 2009-09-17 Vladimir Hanes New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
TW200942242A (en) * 2008-03-10 2009-10-16 Rolf Schurmann New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CN102985070A (zh) * 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的极低剂量的固体口服剂型
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
IT202100008834A1 (it) 2021-04-08 2022-10-08 Ind Chimica Srl Processo per la preparazione di drospirenone come polvere fine tramite duplice cambio di forma cristallina
WO2023152658A1 (en) 2022-02-10 2023-08-17 Lupin Limited Slow release drospirenone tablet composition
US20250186337A1 (en) * 2022-03-01 2025-06-12 Chemo Research, S.L. Chewable oral contraceptive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3051168C2 (de) * 1979-01-24 1998-08-27 Minnesota Mining & Mfg Mono- bzw. Polycarbonsäureester oder deren Gemische oder Ester bzw. deren Gemische aus Isocyanaten und fluor- bzw. chlorhaltigen aliphatischen Alkoholen
DE3051166C2 (en) 1980-06-11 1990-10-18 Schering Ag, 1000 Berlin Und 4709 Bergkamen, De Compsns. for contraception or treatment of gynaecological disorders
DE3347125A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
DE3682130D1 (de) * 1985-07-15 1991-11-28 Japan Res Dev Corp Verfahren zur herstellung von ultrafeinen organischen verbindungen.
DE3916112A1 (de) 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
ZA939566B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for dry blend compression od medicaments.
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE4429374C1 (de) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente
KR100384264B1 (ko) * 1994-09-22 2003-08-30 악조 노벨 엔.브이. 습식과립화에의한 투여단위의제조방법
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
WO1998004267A1 (en) * 1996-07-26 1998-02-05 American Home Products Corporation Progestin/estrogen oral contraceptive
PT917466E (pt) * 1996-07-26 2004-12-31 Wyeth Corp Contraceptivo oral
ES2223081T3 (es) * 1996-07-26 2005-02-16 Wyeth Metodo anticonceptivo oral monofasico y kit que comprende una combinacion de progestina y estrogeno.
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
KR101019361B1 (ko) * 1999-08-31 2011-03-07 바이엘 쉐링 파마 악티엔게젤샤프트 피임약으로서의 사용을 위한 에티닐에스트라디올과드로스피렌온의 약학적 조합
RS52149B (sr) * 2000-01-18 2012-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona

Also Published As

Publication number Publication date
BR0014159A (pt) 2002-05-07
KR20070067248A (ko) 2007-06-27
ATE420648T1 (de) 2009-01-15
NO20020801L (no) 2002-04-26
AU2005202046A1 (en) 2005-06-09
DK1214076T3 (da) 2004-02-23
EP2044941A1 (en) 2009-04-08
DE122009000006I2 (de) 2012-03-22
HRP20070188B1 (hr) 2015-06-19
PL199028B1 (pl) 2008-08-29
JP4354667B2 (ja) 2009-10-28
EP1598069A2 (en) 2005-11-23
EP1598069A3 (en) 2006-04-05
HK1082432A1 (en) 2006-06-09
IL148339A0 (en) 2002-09-12
EP1214076A1 (en) 2002-06-19
NO20020801D0 (no) 2002-02-19
HRP20070188A2 (en) 2007-07-31
DE60006692T2 (de) 2004-09-23
HUP0202500A3 (en) 2004-04-28
EP1214076B1 (en) 2003-11-19
EE200200110A (et) 2003-06-16
HU227207B1 (en) 2010-11-29
JP2003508441A (ja) 2003-03-04
EP1380301B1 (en) 2009-01-14
PT1598069E (pt) 2009-07-20
AU780330B2 (en) 2005-03-17
DE60042089D1 (de) 2009-06-04
DK1598069T3 (da) 2009-07-06
ES2319750T3 (es) 2009-05-12
JP2009143959A (ja) 2009-07-02
AU2010226924A1 (en) 2010-10-28
WO2001015701A1 (en) 2001-03-08
KR20020040798A (ko) 2002-05-30
ES2325589T3 (es) 2009-09-09
HK1061968A1 (en) 2004-10-15
CZ2002615A3 (cs) 2002-08-14
PT1214076E (pt) 2004-04-30
KR100857344B1 (ko) 2008-09-05
ME00329B (me) 2011-05-10
TWI276436B (en) 2007-03-21
RS50262B (sr) 2009-07-15
ATE429231T1 (de) 2009-05-15
SI1214076T1 (en) 2004-06-30
DE60006692D1 (de) 2003-12-24
BG66114B1 (bg) 2011-05-31
HK1047247B (en) 2004-07-23
NO326860B1 (no) 2009-03-02
NZ517845A (en) 2004-12-24
CY1108990T1 (el) 2014-02-12
AU2009200247B2 (en) 2010-07-01
CZ300514B6 (cs) 2009-06-03
DK1380301T3 (da) 2009-04-20
AU2005202046B9 (en) 2008-12-11
ATE254464T1 (de) 2003-12-15
ES2211580T3 (es) 2004-07-16
RS20090134A (sr) 2009-11-10
CY2009015I1 (el) 2014-02-12
EP1598069B1 (en) 2009-04-22
SI1598069T1 (sl) 2009-10-31
DE122009000006I1 (de) 2009-05-07
DE60041421D1 (de) 2009-03-05
AU6589500A (en) 2001-03-26
CY1109252T1 (el) 2014-07-02
PT1380301E (pt) 2009-03-30
RS50262B2 (sr) 2018-10-31
AU2009200247A1 (en) 2009-02-19
EE05128B1 (et) 2009-02-16
DE122009000007I1 (de) 2009-05-07
HUP0202500A2 (en) 2002-10-28
HK1047247A1 (en) 2003-02-14
AU2005202046B2 (en) 2008-11-20
KR101019361B1 (ko) 2011-03-07
DE122009000007I2 (de) 2011-07-21
SI1380301T1 (sl) 2009-06-30
CY2009015I2 (el) 2014-02-12
EP1380301A1 (en) 2004-01-14
PL354406A1 (pl) 2004-01-12
YU14502A (sh) 2006-01-16

Similar Documents

Publication Publication Date Title
MEP36008A (hr) Farmaceutska kombinacija etinilestradiola i drospirenona za primjenu kao kontraceptivnog sredstva
NO179311B (no) Flerfasekombinasjons- og kontraseptiv pakke
KR900701277A (ko) 피임 시스템 및 방법
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
NO327588B1 (no) Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
TR200003788A2 (tr) Yavaş salımlı oral dozaj bileşim.
KR920011514A (ko) 프로게스토겐만을 함유하는 피임제
HRP20090418T1 (hr) Farmaceutski pripravak koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
NO974630D0 (no) Farmasöytisk kombinasjonspreparat for hormonell antikonsepsjon
CY1108265T1 (el) Στερεη διαστοματικη φαρμακευτικη μορφη για αντισυλληψη
KR890009407A (ko) 폐경기증세 및 골다공증의 치료를 위한 약학적 투여단위
US7297688B2 (en) Starter kit for low dose oral contraceptives
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
SE9501671D0 (sv) Method and composition for prevention of posterior capsule opacification
NO20072687L (no) Farmasoytisk prevensjonspreparat
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive method
AR025443A1 (es) Una composicion farmaceutica para ser usada como anticonceptivo.